Abstract: Diabetic kidney disease (DKD) is the main cause of endstage renal disease. At present, multidisciplinary therapeutic strategies based on reninangiotensin system inhibitors and sodiumglucose cotransporter 2 inhibitors is effective for DKD. In recent years, incretinrelated drugs have reported renal function protection in clinical trials. Hypoxiainducible factor prolyl hydroxylase inhibitors may be renoprotective since they improve tubulointerstitial hypoxia. In addition, new drugs, including NFE2related factor 2 agonists, glycation end products (AGE) inhibitors, may also have potential therapeutic effects in DKD. Epigenetic regulation plays an critical role in renal injury and renal function progression in DKD. Molecules with epigenetic regulation such as histone modification inhibitors may become a new way of intervention for DKD in the future.

Key words: diabetic kidney diseases, therapy, glycation end products, epigenetic regulation